展開再生医療の世界市場展望:幹細胞治療、組織工学、遺伝子治療

◆英語タイトル:Translational Regenerative Medicine: Market Prospects 2016-2026
◆商品コード:VGAIN6022519
◆発行会社(リサーチ会社):visiongain
◆発行日:2016年1月
◆ページ数:285
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,799 ⇒換算¥259,056見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥431,856見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥719,856見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
visiongain社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、展開再生医療の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・展開再生医療の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・展開再生医療の世界市場:セグメント別市場分析
 (幹細胞治療、組織工学、遺伝子治療)
・展開再生医療の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

What can be expected from the Translational Regenerative Medicine market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 285-page report provides 170 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of translational regenerative medicine market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Translational regenerative medicine submarkets:
• Stem Cell Therapies
• Tissue Engineering
• Gene Therapies

See revenue forecasts for some the leading products in the market
How will leading drug perform to 2026? Our study forecasts revenues for a number of leading products in the translational regenerative medicine market including:
• Osteocel Plus
• Trinity ELITE
• TEMCELL /Prochymal
• Apligraf
• Dermagraft
• ReCell
• Neovasculgen
• Glybera (alipogene tiparvovec)
• IMLYGIC (talimogene laherparepvec)

See revenue forecasts for the leading regional markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• Europe
• Asia-Pacific
• Rest of World

Leading companies and potential for market growth
Overall revenue for the Translational Regenerative Medicine market will reach $12.1bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain’s analysis of 16 leading companies, including these:
• Alphatec Spine
• Anterogen
• Athersys
• Avita Medical
• AxoGen
• Medipost
• Mesoblast
• NuVasive
• Ocata Therapeutics
• Organogenesis
• Osiris Therapeutics
• Pharmicell
• Regenersys
• TiGenix
• UniQure
• Vericel Corporation

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

【レポートの目次】

1. Report Overview
1.1 Global Translational Regenerative Medicine: Market Overview
1.2 Global Translational Regenerative Medicine Market Definition and Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction To Translational Regenerative Medicine
2.1 What Is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench to Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation And Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2016-2026
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2014 and 2015
3.3 Global Translational Regenerative Medicine: Market Forecast 2016-2026
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares By Sector 2016-2026

4. Stem Cell Therapies: Leading Applications, 2016-2026
4.1 The Global Market for Stem Cell Therapies, 2014 and 2015
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2016-2026
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2016-2026
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2016-2026
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products, 2015
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2016-2026
4.8 Development Pipeline for Stem Cell Therapies, 2016-2026
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Cx601 (TiGenix)
4.8.1.8 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.9 Stempeucel (Stempeutics Research)
4.8.1.10 C-Cure (Cardio3 BioSciences)
4.8.1.11 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem)
4.8.5.4 MultiStem (Athersys)
4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
4.8.5.6 ALD-401 (Cytomedix)
4.8.5.7 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 Stem Cells Therapy Market: Drivers and Restraints 2016-2026

5. Tissue Engineering Therapies: Leading Applications, 2016-2026
5.1 The Global Market for Tissue Engineered Therapies, 2014 and 2015
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2016-2026
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2016-2026
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2016-2026
5.3.5 Epicel (Vericel)
5.3.6 Grafix (Osiris Therapeutics)
5.3.7 MySkin and CyroSkin (Regenerys)
5.3.8 ReCell (Avita Medical)
5.3.8.1 ReCell (Avita Medical): Sales Forecast 2016-2026
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2016-2026
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2016-2026

6. Gene Therapies: Leading Applications, 2016-2026
6.1 The Global Market for Gene Therapies, 2014 and 2015
6.2 Gene Therapies: Global Market Forecast 2016-2026
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2016-2026
6.3.4 Glybera (UniQure)
6.3.4.1 Glybera: Sales Forecast 2016-2026
6.4.1.4 IMLYGIC (talimogene laherparepvec) – (Amgen)
6.4.1.4.1 Clinical Trials and Development Efforts for IMLYGIC
6.4.1.4.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2016-2026
6.4 Development Pipeline For Gene Therapies, 2016-2026
6.4.1 Late-Stage Pipeline Gene Therapies, 2015
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed At Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2016-2026

7. Leading National Markets for Translational Regenerative Medicine, 2016-2026
7.1 The Translational Regenerative Medicine Market by Region
7.1.1 The Global Distribution of Translational Regenerative Medicine in 2014 and 2015
7.2 Leading National Markets: Forecast 2016-2026
7.2.1 Changing Market Shares By Region, 2016-2026
7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2016-2026
7.4 United States: The Largest Translational Regenerative Medicine Market
7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2016-2026
7.4.3 The Regulatory Framework for Regenerative Medicine in the US
7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
7.5 Europe: A Fragmented Regenerative Medicine Market
7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.5.2 European Regenerative Medicine Market: Market Forecast 2016-2026
7.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
7.5.4 Regulation of Regenerative Medicine in the European Union
7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe
7.5.5.1 Regulation of Stem Cell Research in the UK
7.5.6 Russia: Rising Interest in Regenerative Medicine Research
7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2016-2026
7.6.3 Australia: Encouraging Translational Regenerative Medicine
7.6.4 China: Encouraging Stem Cell R&D
7.6.4.1 Government Intervention into TRM Research in China
7.6.4.2 Regulation of Stem Cell Research in China
7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
7.6.5 Japan: Difficulty in Translating Research into Commercialisation
7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine
7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan
7.6.5.3 Regulation of Regenerative Medicine in Japan
7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan
7.6.6 India: An Emerging Market for Regenerative Medicine
7.6.6.1 Efforts in Stem Cell Research in India
7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
7.6.7 South Korea: First to Approve Stem Cell Treatments
7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts
7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming
7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2016-2026

8. The Leading Companies in the the Translational Regenerative Medicine Market, 2016-2026
8.1 Translational Regenerative Medicine: A Hotbed for Innovation
8.2 Alphatec Spine
8.2.1 Alphatec Spine: Financial and Performance Analysis, 2009-2014
8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices
8.3 Anterogen
8.3.1 Anterogen: Pipeline Analysis, 2015
8.4 Athersys
8.4.1 Athersys: Financial and Performance Analysis, 2010-2014
8.4.2 Athersys: Pipeline Analysis, 2015
8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases
8.5 Avita Medical
8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015
8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015
8.5.3 Avita Medical: Pipeline Analysis, 2015
8.6 AxoGen
8.6.1 AxoGen: Historical Financial and Performance Analysis, 2010-2014
8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015
8.6.3 AxoGen: Pipeline Analysis, 2015
8.8 Medipost
8.7.1 Medipost: Historical Financial and Performance Analysis, 2010-2014
8.7.2 Medipost: Regenerative Medicine Portfolio, 2015
8.7.3 Medipost: Pipeline Analysis, 2015
8.8 Mesoblast
8.8.1 Mesoblast Product Portfolio, 2015
8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015
8.8.3 Mesoblast: Pipeline Analysis, 2015
8.8.3.1 NeoFuse
8.8.3.2 Chondrogen
8.8.3.3 Prochymal / TEMCELL
8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
8.9 NuVasive
8.9.1 NuVasive Product Portfolio, 2015
8.9.2 NuVasive: Historical Financial and Performance Analysis, 2009-2013
8.9.3 NuVasive: Pipeline Analysis, 2015
8.10 Ocata Therapeutics
8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2009-2014
8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015
8.10.2.1 Retinal Pigment Epithelial Cell Therapy
8.10.3 Ocata’s Other Therapeutic Platforms
8.11 Organogenesis
8.11.1 Organogenesis RM Portfolio, 2015
8.11.2 Organogenesis: Pipeline Analysis, 2015
8.12 Osiris Therapeutics
8.12.1 Osiris Therapeutics: RM Portfolio, 2015
8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2010-2014
8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015
8.13 Pharmicell
8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2010-2014
8.13.2 Pharmicell: Pipeline Analysis, 2015
8.14 Regenerys
8.14.1 Regenerys: RM Portfolio, 2015
8.14.2 Regenerys: Pipeline Analysis, 2015
8.15 TiGenix
8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2014
8.15.2 TiGenix: Pipeline Analysis, 2015
8.16 UniQure
8.16.1 UniQure: Pipeline Analysis, 2015
8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)

9. Qualitative Analysis of the Translational Regenerative Medicine Market, 2015
9.1 Market Factors Influencing the Translational Regenerative Medicine Market
9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.3 Strengths
9.3.1 Improvements in Regulatory Frameworks
9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
9.3.3 Strong Support from Governments in Multiple Regions
9.3.4 Increasing Ease of Product Commercialisation and Market Access
9.4 Weaknesses
9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
9.4.2 Lack of Funding from Venture Capital
9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
9.4.4 Successful Commercialisation of TRM Products Requires New Business Models
9.5 Opportunities
9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
9.6 Threats
9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine
9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
9.6.4 Restraints on Reimbursement May Slow Growth
9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.7.1 Threat of New Entrants
9.7.2 Threat of Substitutes
9.7.3 Power of Suppliers
9.7.4 Power of Buyers
9.6.5 Rivalry among Competitors

10. Research Interviews
10.1 Interview with Dr Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies
10.1.1 Naïve State Stem Cells Could Significantly Impact the Regenerative Medicine Market
10.1.2 On Relationships between Big Pharma and Smaller Biotech Companies in the Translational Regenerative Market
10.1.3 Growth of Minerva Biotechnologies
10.1.4 Possible New Commercial Applications for Regenerative Medicine
10.1.5 Translational Regenerative Medicine in Emerging Markets
10.1.6 iPS Cells – The Future of Stem Cell Therapies?
10.1.7 On Drivers and Restraints in the Translational Regenarative Medicine Market in 2016
10.2 Interview with Dr Yael Margolin, CEO of Gamida Cell Ltd.
10.2.1 Progress of NiCord in the Blood Cancer Indication
10.2.2 On Drivers and Restraints in the Blood Cancer Market in 2015
10.2.3 Growth of Gamida Cell Ltd.

11. Conclusion
11.1 Overview of Current Market Conditions and Market Forecast, 2014-2026
11.2 Leading Regenerative Medicine Segments in 2014 and 2015
11.3 Leading Regions in the Translational Regenerative Medicine Market in 2014 And 2015
11.4 Future Outlook for the Various Sectors within TRM, 2016-2026
11.5 R&D Pipeline Products Crucial to Future Market Growth
11.6 What Does the Future Hold for Regenerative Medicine?

12. Glossary

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 1.1 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2014-2020 (Altered Data)
Table 1.2 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2020-2026 (Altered Data)
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2015
Table 2.2 Potency and Source of Stem Cells, 2016
Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2016
Table 2.4 Major Types Of Stem Cells and Their Properties, 2016
Table 2.5 Terminology For Stem Cell Donor-Types, 2016
Table 2.6 Clinical Trial Phases, 2016
Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2014 and 2015
Table 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2014-2020
Table 3.3 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2020-2026
Table 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2020, 2020-2026 and 2014-2026
Table 3.5 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014, 2020 and 2026
Table 3.6 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014, 2020 and 2026
Table 4.1 Selected Stem Cell Products Currently Available On The Market, 2015
Table 4.2 Stages of Osteogenesis, 2015
Table 4.3 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.4 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.5 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 4.6 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 4.7 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.8 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.9 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.10 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.11 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
Table 5.1 Selected Tissue Engineering Products Currently Available on the Market, 2015
Table 5.2 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.3 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.4 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.5 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.6 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.7 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.8 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.9 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.10 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2015
Table 6.1 Currently Available Gene Therapy Products, 2015
Table 6.2 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 6.3 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 6.4 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 6.5 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 6.6 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 6.7 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 6.8 Amgen: Gene Therapy Clinical Trials, 2015
Table 6.9 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2014-2026
Table 6.10 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2014-2026
Table 6.11 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
Table 6.12 Advantegene: Gene Therapy Clinical Trials, 2015
Table 6.13 Spark Therapeutics: Gene Therapy Clinical Trials, 2015
Table 6.14 Recent Developments in Gene Therapy for Use in Diabetes
Table 6.15 Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2015
Table 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) and Market Share (%) by Region, 2014 and 2015
Table 7.2 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2014-2020
Table 7.3 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2020-2026
Table 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2020, 2020-2026, 2014-2026
Table 7.5 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2014, 2020 and 2026
Table 7.6 US Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014, 2020 and 2026
Table 7.7 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.8 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.9 European Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014, 2020 and 2026
Table 7.10 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.11 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.12 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2026
Table 7.13 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.15 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2026
Table 7.16 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.17 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 8.1 Alphatec Spine: Historical Sales ($m) and Operating Profit / Loss ($m), 2009-2014
Table 8.2 Alphatec Spine: Regenerative Medicine Clinical Trials, 2015
Table 8.3 Anterogen: Regenerative Medicine Clinical Trials, 2015
Table 8.4 Athersys: Historical Sales ($m) 2010-2014
Table 8.5 Athersys: Historical Expenditure and Losses ($m) 2010-2014
Table 8.6 Athersys: Regenerative Medicine Clinical Trials, 2015
Table 8.7 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2015
Table 8.8 Avita Medical: Regenerative Medicine Clinical Trials, 2015
Table 8.9 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2014
Table 8.10 AxoGen: Regenerative Medicine Clinical Trials, 2015
Table 8.11 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2010-2014
Table 8.12 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2010-2014
Table 8.13 Medipost: Regenerative Medicine Clinical Trials, 2015
Table 8.14 Mesoblast: Historical Sales ($m, AUD m), 2010-2015
Table 8.15 Mesoblast: Regenerative Medicine Clinical Trials, 2015
Table 8.16 NuVasive: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2009-2014
Table 8.17 NuVasive: Regenerative Medicine Clinical Trials, 2015
Table 8.18 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2014
Table 8.19 Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2015
Table 8.20 Organogenesis: Regenerative Medicine Clinical Trials, 2015
Table 8.21 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2014
Table 8.22 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015
Table 8.23 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014
Table 8.24 Regenerys: Regenerative Medicine Clinical Trials, 2015
Table 8.25 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2011-2014
Table 8.26 TiGenix: Regenerative Medicine Clinical Trials, 2015
Table 8.27 UniQure: Regenerative Medicine Clinical Trials, 2015
Table 8.28 Vericel: Historical Sales ($m and AGR%), 2011-2014
Table 8.29 Vericel: Sales by Product ($m) and Revenue Share (%), 2013-2014
Table 8.30 Vericel Corporation: Regenerative Medicine Clinical Trials, 2015
Table 9.1 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2016-2026
Table 11.1 Global Translational Regenerative Medicine: Market Forecast ($m, CAGR%), 2014, 2018, 2022, 2026
Table 11.2 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2014
Table 11.3 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Region, 2014, 2020 and 2026
Table 11.4 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2015, 2020 and 2026
Table 11.5 Global Translational Regenerative Medicine Market: Products In Late Stage Development, 2015

List of Figures
Figure 1.1 Global Translational Regenerative Medicine Market: Submarkets, 2016
Figure 2.1 Brief History of Stem Cell Research, 1900-2015
Figure 2.2 Examples of FDA-Approved Tissue Engineering Products
Figure 2.3 Brief History of Tissue Engineering, 1900-2015
Figure 2.4 Brief History of Gene Therapy, 1970-2015
Figure 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014 and 2015
Figure 3.2 The Gene Therapy Market: Revenue ($m), 2014 and 2015
Figure 3.3 The Global Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2020
Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2020-2026
Figure 3.6 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2026
Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014, 202 0 and 2026
Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014
Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2020
Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2026
Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 4.5 Stem Cell Therapies: Drivers and Restraints, 2016-2026
Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.4 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.5 Tissue Engineered Therapy Products: Drivers and Restraints, 2016-2026
Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.3 Glybera Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.4 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.5 Gene Therapy Products: Market Drivers and Restraints, 2016-2026
Figure 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) by Region, 2014 and 2015
Figure 7.2 Asia-Pacific, Europe, US, and ‘Rest of the World’ Translational Regenerative Medicine Market: Market Forecast ($m), 2014-2026
Figure 7.3 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2020
Figure 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2020-2026
Figure 7.5 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2026
Figure 7.6 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2014
Figure 7.7 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2020
Figure 7.8 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2026
Figure 7.9 US Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026
Figure 7.10 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 7.11 European Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026
Figure 7.12 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 7.13 Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026
Figure 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 7.15 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 8.1 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2009-2014
Figure 8.2 Athersys: Historical Sales ($m) 2010-2014
Figure 8.3 Athersys: Historical Revenue, Expenditure and Losses ($m) 2010-2014
Figure 8.4 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2014
Figure 8.5 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2014
Figure 8.6 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014
Figure 8.7 Medipost: Revenue Share by Business Area (%), 2012
Figure 8.8 Medipost: Revenue Share by Business Area (%), 2013
Figure 8.9 Medipost: Revenue Share by Business Area (%), 2014
Figure 8.10 Mesoblast: Historical Sales ($m, AUD m), 2011-2014
Figure 8.11 NuVasive: Historical Sales and Net Income (Profits and Losses) ($m), 2009-2014
Figure 8.12 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2014
Figure 8.13 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2014
Figure 8.14 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2010-2014
Figure 8.15 TiGenix: Historical Sales ($m) and Net Income ($m), 2011-2014
Figure 8.16 Vericel: Historical Sales ($m), 2011-2014 (Limited Scale)
Figure 8.17 Vericel: Historical Sales ($m), 2011-2014 (Full Scale)
Figure 8.18 Vericel: Revenue Contribution by Product (%) 2014
Figure 9.1 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016
Figure 11.1 Global Translational Regenerative Medicine: Market Forecast ($m), 2014, 2020 and 2026
Figure 11.2 Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014
Figure 11.3 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2014-2026

【レポートのキーワード】

展開再生医療、幹細胞治療、組織工学、遺伝子治療

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[展開再生医療の世界市場展望:幹細胞治療、組織工学、遺伝子治療]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆